Figure 6
Figure 6. DFS by TP1 MRD and MRD/white cell count interaction. (A) DFS according to TP1 MRD status in unselected patients; DFS according to TP1 MRD status and white blood cell (WBC) count (×109/L) in (B) B-precursor ALL and (C) T-precursor ALL. DFS probability at 4 to 5 years: MRDneg 0.63 versus MRDlow-pos (< −4) 0.30 versus MRDpos (≥−4) 0.15; B-precursor: MRDneg 0.73 versus MRDpos (any level) with WBC of 30 × 109/L or less, 0.18 and WBC more than 30 × 109/L, 0; T-precursor: MRDneg 0.44 versus MRDpos (any level) with WBC lower than or equal to or more than 100 × 109/L, 0 (C).

DFS by TP1 MRD and MRD/white cell count interaction. (A) DFS according to TP1 MRD status in unselected patients; DFS according to TP1 MRD status and white blood cell (WBC) count (×109/L) in (B) B-precursor ALL and (C) T-precursor ALL. DFS probability at 4 to 5 years: MRDneg 0.63 versus MRDlow-pos (< −4) 0.30 versus MRDpos (≥−4) 0.15; B-precursor: MRDneg 0.73 versus MRDpos (any level) with WBC of 30 × 109/L or less, 0.18 and WBC more than 30 × 109/L, 0; T-precursor: MRDneg 0.44 versus MRDpos (any level) with WBC lower than or equal to or more than 100 × 109/L, 0 (C).

Close Modal

or Create an Account

Close Modal
Close Modal